EverEdge Global

headquartered in New Zealand, publishes valuation models spanning ten distinct IP asset classes relevant to pharmaceutical and biotech portfolios.

Country: NZ

Coverage

	CN	EU	IN	US
regulatory-legal	✓	✓	✓	✓

Verifiable facts

Fact	Value	Source
Funding	Unattributed venture capital investment and share purchase agreements with investors including Punakaiki Fund; some sources indicate no funding raised medium confidence	prospeo.io · nbr.co.nz
Capacity	Not applicable; the company is an intangible asset advisory firm, not a manufacturer	m.scoop.co.nz
Certification	Company professionals hold various certifications (e.g., CVA, CPVA, RMC, CA) but the firm itself is an advisory service, not a manufacturer with industrial certifications medium confidence	gobusiness.gov.sg
Regulatory approval	Not applicable; the company provides advisory services and does not hold regulatory approvals for products itself, though it advises clients on them	cfotechoutlook.com · everedgeglobal.com · gobusiness.gov.sg
Production site	Not applicable; the company is an intangible asset advisory firm, though it manages a subsidiary, EverEdge Capital, which has acquired manufacturing businesses like Accord Precision Limited	m.scoop.co.nz
Headcount	Estimated between 1 and 31 employees medium confidence	prospeo.io · datanyze.com
Revenue	Estimated annual revenue figures range from approximately $427,775 to $5 million medium confidence	prospeo.io · datanyze.com · everedgeglobal.com

Independent sources: cfotechoutlook.com · datanyze.com · gobusiness.gov.sg · m.scoop.co.nz · nbr.co.nz · prospeo.io

Technologies

Name	Cluster	Risk
Biotech IP valuation	regulatory-legal	Low	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.